Integrating PET/CT into breast Cancer care: a review of recent developments.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-06-18 DOI:10.1080/14737140.2025.2513450

Serin Moghrabi, Raghad Mohammad Al-Houwari, Hikmat Abdel-Razeq, Asem Mansour, Miriam Mikhail-Lette, Ahmed Saad Abdlkadir, Saad Ruzzeh, Diana Paez, Christopher Marton, Akram Al-Ibraheem

{"title":"Integrating PET/CT into breast Cancer care: a review of recent developments.","authors":"Serin Moghrabi, Raghad Mohammad Al-Houwari, Hikmat Abdel-Razeq, Asem Mansour, Miriam Mikhail-Lette, Ahmed Saad Abdlkadir, Saad Ruzzeh, Diana Paez, Christopher Marton, Akram Al-Ibraheem","doi":"10.1080/14737140.2025.2513450","DOIUrl":null,"url":null,"abstract":"Introduction: Breast cancer (BC) is the most common malignancy in women, classified by histopathological type, grade, receptor status, and stage. PET/CT, particularly with 1 8 F-FDG, plays a vital role in staging, detecting metastases, and assessing treatment response. This review explores the role of PET/CT in BC management and emerging radiotracers for enhanced diagnosis. A comprehensive literature search was conducted in PubMed and Scopus, covering studies from January 2000 to March 2025.Areas covered: The paper examines how 1 8 F-FDG-PET/CT findings are influenced by BC classifications such as histopathological type, grade, receptor status, and stage. FDG uptake varies across subtypes, affecting prognosis and treatment decisions, with limitations noted in hormone receptor-positive cancers. The review also investigates emerging radiotracers, including those targeting estrogen and HER2 receptors, which may improve diagnostic accuracy and potentially replace 1 8 F-FDG in specific settings. Additionally, theranostic approaches are highlighted, offering personalized treatment based on molecular profiles.Expert opinion: We recommend that physicians incorporate pathological analysis, including histopathological type, grade, and molecular status, when selecting the most appropriate radiotracer for BC diagnostics and treatment. Further research and clinical trials on emerging tracers and theranostic agents are essential to confirm their efficacy and safety.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2513450","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Breast cancer (BC) is the most common malignancy in women, classified by histopathological type, grade, receptor status, and stage. PET/CT, particularly with ^{1 8} F-FDG, plays a vital role in staging, detecting metastases, and assessing treatment response. This review explores the role of PET/CT in BC management and emerging radiotracers for enhanced diagnosis. A comprehensive literature search was conducted in PubMed and Scopus, covering studies from January 2000 to March 2025.

Areas covered: The paper examines how ^{1 8} F-FDG-PET/CT findings are influenced by BC classifications such as histopathological type, grade, receptor status, and stage. FDG uptake varies across subtypes, affecting prognosis and treatment decisions, with limitations noted in hormone receptor-positive cancers. The review also investigates emerging radiotracers, including those targeting estrogen and HER2 receptors, which may improve diagnostic accuracy and potentially replace ^{1 8} F-FDG in specific settings. Additionally, theranostic approaches are highlighted, offering personalized treatment based on molecular profiles.

Expert opinion: We recommend that physicians incorporate pathological analysis, including histopathological type, grade, and molecular status, when selecting the most appropriate radiotracer for BC diagnostics and treatment. Further research and clinical trials on emerging tracers and theranostic agents are essential to confirm their efficacy and safety.

查看原文本刊更多论文

将PET/CT整合到乳腺癌治疗中：最新进展综述。

乳腺癌（BC）是女性中最常见的恶性肿瘤，根据组织病理类型、分级、受体状态和分期进行分类。PET/CT，特别是18 F-FDG，在分期、检测转移和评估治疗反应方面起着至关重要的作用。本文综述了PET/CT在BC治疗中的作用以及新出现的增强诊断的放射性示踪剂。在PubMed和Scopus中进行了全面的文献检索，涵盖了2000年1月至2025年3月的研究。涵盖领域：本文研究了18个F-FDG-PET/CT结果如何受到BC分类的影响，如组织病理类型、分级、受体状态和分期。FDG摄取因亚型而异，影响预后和治疗决策，在激素受体阳性的癌症中存在局限性。本综述还研究了新兴的放射性示踪剂，包括那些靶向雌激素和HER2受体的示踪剂，它们可能提高诊断准确性，并可能在特定情况下取代18 F-FDG。此外，治疗方法被强调，提供基于分子谱的个性化治疗。专家意见：我们建议医生在选择最合适的BC诊断和治疗放射性示踪剂时，结合病理分析，包括组织病理类型、分级和分子状态。对新出现的示踪剂和治疗剂进行进一步的研究和临床试验是确认其有效性和安全性的必要条件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.